BioPharm International-11-01-2005

Achieving approval of a new pharmacologic agent or device on a worldwide basis is a significant challenge. The guidelines and requirements that steer our efforts at enhancing and extending life around the world are tedious and, fortunately, comprehensive. In spite of relatively few setbacks, perhaps in no other category than pharmaceutical development are the advantages of these guidelines more evident.

For those conducting clinical trials, strict adherence to state regulatory requirements makes sound business sense.

"Smart" tags speak only when spoken to. "Brilliant" tags are capable of independent decision-making.

Facts@FDA...ultimately will contain current product labeling information plus safety data gleaned from adverse event reports.

Simple practices can increase profit margins and ensure gas supply.

According to a 2005 study by the American Academy of Neurology, donepezil may improve the memory of Alzheimers patients and those suffering with multiple sclerosis.

When devising business strategy or making a career move, one always looks for growth. That's precisely what has brought me to BioPharm International.

Validation of a cleaning process demonstrates that it can reliably and effectively remove residue to an acceptable level.

In the fast-changing pharmaceutical industry, adaptable planning provides a competitive edge.

Use of a fermentor for cell culture study advances research in directions previously thought unimaginable.

BioPharm International is about to embark on another new beginning. You'll remember the magazine (along with the primers, supplements and media kit) had a drastic new beginning in February of 2004 when we launched the major redesign. There were other new beginnings in the past two and one-half years, like five new columns (StreetTalk, Operations Excellence, BioPartnerships, Compliance Briefing and Final Word.) You'll even see a sixth column about legal issues in 2006.